Premium
Duration of dual anti‐platelet therapy following drug eluting stents
Author(s) -
Bang Vigyan V.,
Levy Michael S.
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26491
Subject(s) - medicine , conventional pci , drug eluting stent , randomized controlled trial , stent , platelet aggregation inhibitor , drug , cardiology , acute coronary syndrome , surgery , aspirin , restenosis , myocardial infarction , pharmacology
Key Points This meta‐analysis suggests that abbreviated DAPT (<6 months) could be considered in patients undergoing PCI with current generation drug eluting stents (DES). Extended DAPT strategy (>1 year) may be appropriate in those patients in whom prevention of stent and non‐stent‐related coronary events are likely to offset the bleeding complications. Additional randomized trials are needed to evaluate the optimum duration of DAPT in patients with the latest generation DES and current antiplatelet drugs.